Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Major Shareholder Bain Capital Life Sciences Inv Acquires 300,000 Shares

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) major shareholder Bain Capital Life Sciences Inv purchased 300,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 8th. The shares were purchased at an average cost of $5.76 per share, for a total transaction of $1,728,000.00. Following the completion of the transaction, the insider now owns 7,800,000 shares in the company, valued at approximately $44,928,000. This represents a 4.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Olema Pharmaceuticals Price Performance

Shares of OLMA opened at $5.52 on Thursday. The company has a market cap of $316.28 million, a P/E ratio of -2.52 and a beta of 2.05. The stock has a fifty day moving average price of $8.07 and a 200 day moving average price of $10.92. Olema Pharmaceuticals, Inc. has a 12 month low of $4.60 and a 12 month high of $16.77.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OLMA. Victory Capital Management Inc. grew its stake in shares of Olema Pharmaceuticals by 9.9% in the third quarter. Victory Capital Management Inc. now owns 851,512 shares of the company’s stock worth $10,167,000 after purchasing an additional 76,720 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Olema Pharmaceuticals by 168.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 330,761 shares of the company’s stock worth $3,949,000 after purchasing an additional 207,565 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Olema Pharmaceuticals by 10.8% in the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock worth $11,972,000 after purchasing an additional 97,428 shares in the last quarter. Point72 Asset Management L.P. bought a new position in shares of Olema Pharmaceuticals in the second quarter worth $34,753,000. Finally, Barclays PLC grew its stake in shares of Olema Pharmaceuticals by 105.0% in the third quarter. Barclays PLC now owns 94,915 shares of the company’s stock worth $1,133,000 after purchasing an additional 48,614 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $27.00.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.